ONCY Oncolytics Biotech Inc

$1.74 $-0.07 (-3.87%)
Overall

ONCY Stock Analysis Overview

What this means: InvestorsObserver gives Oncolytics Biotech Inc (ONCY) an overall rank of 47, which is below average. Oncolytics Biotech Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 47 means that 53% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ONCY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ONCY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ONCY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ONCY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ONCY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ONCY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ONCY Stock Analysis Overview

What this means: InvestorsObserver gives Oncolytics Biotech Inc (ONCY) an overall rank of 47, which is below average. Oncolytics Biotech Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 47 means that 53% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AMZN report

ONCY Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ONCY Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ONCY Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ONCY Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ONCY Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ONCY Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Oncolytics Biotech Inc (ONCY) Analyst Forecast

ONCY Price, Volume, Earnings, and Dividend Date

  • Last Price $1.74
  • Previous Close $1.81
  • Change $-0.07
  • Open $1.80
  • Volume 244,926
  • Avg. Volume (100-day) 207,568
  • Market Cap 95,747,194
  • Days Range 1.7201 - 1.81
  • 52-week Range 1.69 - 4.83
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 02/03/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.616
  • PEG Ratio

Oncolytics Biotech Inc (ONCY) Company Description

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

Oncolytics Biotech Inc (ONCY) Stock Chart

My Watchlists

Follow Your Favorite Stocks